Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07179159Not ApplicableRecruiting

Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial

Role: collaborator

NCT07335406Recruiting

Registry for the Management of Helicobacter Pylori Infection in Shandong Province

Role: collaborator

NCT07285096Recruiting

P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Role: collaborator

NCT06723197Phase 4Recruiting

Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication

Role: collaborator

NCT06299605Not ApplicableEnrolling By Invitation

Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori

Role: collaborator

NCT05997433Not ApplicableUnknown

Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)

Role: collaborator

All 6 trials loaded